Modified factor VII
AssigneesZymoGenetics, Inc., Novo Nordisk A/S
InventorsKathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
Life of this patent
Estimating the term…
Abstract
The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
Claims9
A polynucleotide molecule comprising two operatively linked sequence coding regions encoding, respectively, a pre-pro peptide and a gla domain of a vitamin K-dependent plasma protein, and a gla domain-less human Factor VII having at least one amino acid substitution or deletion in a catalytic triad of Ser, Asp and His, wherein upon expression said polynucleotide encodes a modified human Factor VII molecule that has a reduced ability to activate human plasma Factors X or IX and wherein said modified Factor VII inhibits coagulation of human plasma.
Dependencies are inferred from the claim text.